Ownership and insider activity for ImageneBio Inc (IMA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc.
Price
| Price | $4.93 |
| Market Cap | $56M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-14 | Yarema Kristin | A-Award | 254,800 | |
| 2026-08-14 | Yarema Kristin | A-Award | 250,000 | $1.5M |
| 2026-08-14 | Yarema Kristin | A-Award | 137,200 | $801K |
| 2026-08-14 | Grant-Huerta Yanina | A-Award | 39,000 | |
| 2026-08-14 | Grant-Huerta Yanina | A-Award | 65,000 | |
| 2026-08-14 | Grant-Huerta Yanina | A-Award | 56,000 | $327K |
| 2026-07-20 | Grant-Huerta Yanina | |||
| 2026-07-25 | Yarema Kristin | J-Other | 115,129 | |
| 2026-07-25 | Yarema Kristin | M-Exempt | 38,376 | |
| 2026-07-25 | Yarema Kristin | M-Exempt | 38,376 |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.2M | $82.1M | $162.5M | $232.2M | $59.9M | $119.9M | $39.4M | $35.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | $97.0M | $55.6M | $85.0M | $40.8M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.3M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $20.0M | $85.2M | $166.0M | $236.5M | $160.0M | $178.7M | $127.2M | $140.3M |
| Property, Plant & Equipment | $696000 | $769000 | $1.6M | $9.0M | $8.5M | $8.0M | $4.2M | $790000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $20.7M | $86.0M | $168.4M | $247.9M | $172.3M | $192.1M | $141.5M | $153.0M |
| Accounts Payable | $2.3M | $935000 | $2.1M | $2.4M | $2.1M | $2.1M | $897000 | $1.4M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $3.8M | $24.3M | $28.3M | $27.2M | $21.5M | $14.2M | $10.8M | $11.2M |
| Long-term Debt | $62.6M | 0 | 0 | 0 | 0 | 0 | 0 | $7.0M |
| Total Liabilities | $66.5M | $147.4M | $269.5M | $40.0M | $25.3M | $22.3M | $15.6M | $19.8M |
| Retained Earnings | -$50.3M | -$67.1M | -$111.3M | -$145.5M | -$214.2M | -$282.4M | -$331.6M | -$230.1M |
| Total Equity | -$45.8M | -$61.5M | -$101.0M | $207.9M | $147.0M | $169.8M | $125.9M | $133.1M |
| Total Debt | $62.6M | 0 | $186000 | $7.0M | $5.7M | $10.7M | $7.5M | $10.0M |
| Net Debt | $44.4M | -$82.1M | -$162.3M | -$225.2M | -$151.3M | -$164.7M | -$116.9M | -$65.8M |
| Working Capital | $16.2M | $60.9M | $137.6M | $209.3M | $138.5M | $164.5M | $116.4M | $129.1M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 21.47 |
Profitability
| Return on Equity | -38.99% |
| Return on Invested Capital | -39.76% |
| Return on Assets | -34.52% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARTV · CNTB · CNTX · IFRX · KLRS · MGX · OVID
Explore sector: Healthcare · Biotechnology
More sections of IMA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks